{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T03:11:58Z","timestamp":1785553918729,"version":"3.56.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ijrobp.2021.06.030","type":"journal-article","created":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T00:15:57Z","timestamp":1634170557000},"page":"841-850","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Clinical Outcomes Confirm Conjecture: Modern Radiation Therapy Reduces the Risk of Late Toxicity in Survivors of Hodgkin Lymphoma"],"prefix":"10.1016","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0037-6967","authenticated-orcid":false,"given":"Sarah A.","family":"Milgrom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Bakst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda A.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2021.06.030_bib0001","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1182\/blood.V59.3.455.455","article-title":"The management of stage I\u2014II Hodgkin's disease with irradiation alone or combined modality therapy: The Stanford experience","volume":"59","author":"Hoppe","year":"1982","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0002","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1200\/JCO.2003.07.131","article-title":"Long-term cause-specific mortality of patients treated for Hodgkin's disease","volume":"21","author":"Aleman","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0003","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1182\/blood-2010-04-278796","article-title":"Morbidity and mortality in long-term survivors of Hodgkin lymphoma: A report from the Childhood Cancer Survivor Study","volume":"117","author":"Castellino","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0004","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2002.08.021","article-title":"Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger","volume":"20","author":"Ng","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0005","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin's Lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0006","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","article-title":"Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma","volume":"34","author":"van Nimwegen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0007","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2002-02-0634","article-title":"Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: Long-term risks and risk factors","volume":"100","author":"Ng","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0008","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJM199603213341201","article-title":"Breast cancer and other second neoplasms after childhood Hodgkin's disease","volume":"334","author":"Bhatia","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0009","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/jama.290.4.465","article-title":"Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease","volume":"290","author":"Travis","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0010","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/oxfordjournals.annonc.a057774","article-title":"Late cardiac effects after mantle radiotherapy in patients with Hodgkin's disease","volume":"1","author":"Gustavsson","year":"1990","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0011","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0360-3016(96)00295-7","article-title":"Symptomatic coronary artery disease after mantle irradiation for Hodgkin's disease","volume":"36","author":"King","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0012","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","article-title":"Late cardiotoxicity after treatment for Hodgkin lymphoma","volume":"109","author":"Aleman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0013","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1182\/blood-2010-06-291328","article-title":"Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation","volume":"117","author":"Galper","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0014","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk","volume":"175","author":"van Nimwegen","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"Suppl 1","key":"10.1016\/j.ijrobp.2021.06.030_bib0015","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/annonc\/13.S1.79","article-title":"The involved field is back: Issues in delineating the radiation field in Hodgkin's disease","volume":"13","author":"Yahalom","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0016","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: Field and dose guidelines from the international lymphoma radiation oncology group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0017","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0018","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: Final analysis of the German Hodgkin Study Group HD11 trial","volume":"28","author":"Eich","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0019","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1748-717X-2-13","article-title":"A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: Reduction in normal tissue dose and second cancer risk","volume":"2","author":"Koh","year":"2007","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0020","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/pbc.24861","article-title":"The impact of involved node, involved field and mantle field radiotherapy on estimated radiation doses and risk of late effects for pediatric patients with Hodgkin lymphoma","volume":"61","author":"Maraldo","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0021","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/annonc\/mdr439","article-title":"Minimising critical organ irradiation in limited stage Hodgkin lymphoma: A dosimetric study of the benefit of involved node radiotherapy","volume":"23","author":"Campbell","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0022","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ijrobp.2017.05.004","article-title":"Evidence-based review on the use of proton therapy in lymphoma from the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee","volume":"99","author":"Tseng","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0023","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.ijrobp.2011.09.020","article-title":"Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma","volume":"83","author":"Maraldo","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0024","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.01186","article-title":"Impact of risk-adapted therapy for pediatric Hodgkin lymphoma on risk of long-term morbidity: A report from the Childhood Cancer Survivor Study","author":"Oeffinger","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0025","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0026","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: Final results of the randomized EORTC\/LYSA\/FIL H10 Trial","volume":"35","author":"Andre","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0027","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: Final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0028","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2013.52.5410","article-title":"Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: A report from the Children's Oncology Group Study AHOD0031","volume":"32","author":"Friedman","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0029","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/bjh.16014","article-title":"Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): A report from the Children's Oncology Group","volume":"187","author":"Kelly","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0030","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijrobp.2016.10.004","article-title":"Secondary breast cancer risk by radiation volume in women with Hodgkin lymphoma","volume":"97","author":"Conway","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0031","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1200\/JCO.2008.19.9174","article-title":"Breast cancer risk in female survivors of Hodgkin's lymphoma: Lower risk after smaller radiation volumes","volume":"27","author":"De Bruin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0032","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1093\/annonc\/mdl302","article-title":"Second malignancy risk associated with treatment of Hodgkin's lymphoma: Meta-analysis of the randomised trials","volume":"17","author":"Franklin","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0033","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1200\/JCO.2007.15.1001","article-title":"Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: A question of field size","volume":"26","author":"Campbell","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0034","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1001\/jamapediatrics.2019.3807","article-title":"Association of breast cancer risk after childhood cancer with radiation dose to the breast and anthracycline use: A report from the Childhood Cancer Survivor Study","volume":"173","author":"Veiga","year":"2019","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0035","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ijrobp.2017.07.016","article-title":"Breast cancer risk after radiation therapy for Hodgkin lymphoma: Influence of gonadal hormone exposure","volume":"99","author":"Krul","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0036","doi-asserted-by":"crossref","first-page":"l6794","DOI":"10.1136\/bmj.l6794","article-title":"Major cardiac events for adult survivors of childhood cancer diagnosed between 1970 and 1999: Report from the Childhood Cancer Survivor Study cohort","volume":"368","author":"Mulrooney","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0037","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.13935","article-title":"Assessment of radiation doses delivered to organs at risk among patients with early-stage favorable Hodgkin lymphoma treated with contemporary radiation therapy","volume":"3","author":"Pinnix","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14338\/IJPT-20-00010.1","article-title":"Reducing heart dose with protons and cardiac substructure sparing for mediastinal lymphoma treatment","volume":"7","author":"Taparra","year":"2020","journal-title":"Int J Part Ther"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0039","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/S1470-2045(14)70409-7","article-title":"Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: A report from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"16","author":"Armenian","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0040","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.radonc.2006.05.015","article-title":"Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines","volume":"79","author":"Girinsky","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0041","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.ijrobp.2012.08.041","article-title":"Involved node radiation therapy: An effective alternative in early-stage hodgkin lymphoma","volume":"85","author":"Maraldo","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0042","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.03286","article-title":"Excellent outcome for pediatric patients with high-risk Hodgkin lymphoma treated with brentuximab vedotin and risk-adapted residual node radiation","author":"Metzger","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0043","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.21.00108","article-title":"Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma","author":"Kumar","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib0044","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/0284186X.2014.932435","article-title":"Prospective phase II trial of image-guided radiotherapy in Hodgkin lymphoma: Benefit of deep inspiration breath-hold","volume":"54","author":"Petersen","year":"2015","journal-title":"Acta Oncol"},{"issue":"4","key":"10.1016\/j.ijrobp.2021.06.030_bib45","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv008","article-title":"Risk of valvular heart disease after treatment for Hodgkin lymphoma","volume":"107","author":"Cutter","year":"2015","journal-title":"J Natl Cancer Inst."},{"key":"10.1016\/j.ijrobp.2021.06.030_bib46","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1001\/jama.1993.03510160067031","article-title":"Factors affecting late mortality from heart disease after treatment of Hodgkin\u2019s disease","volume":"270","author":"Hancock","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2021.06.030_bib47","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood-2016-09-740332","article-title":"Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines","volume":"129","author":"van Nimwegen","year":"2017","journal-title":"Blood"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301621007562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301621007562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:55:14Z","timestamp":1759744514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301621007562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0360301621007562"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2021.06.030","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Outcomes Confirm Conjecture: Modern Radiation Therapy Reduces the Risk of Late Toxicity in Survivors of Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2021.06.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}